Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
762.140.06%
QQQ
716.210.1%
BTC/USD
76456.010.3258%
DIA
517.960.08%
GLD
397.980.1%
TLT
81.720.07%

Damora Therapeutics Inc (DMRA) Stock Price, Quote, News & History

DMRANASDAQ
Trade with Public
Trade with Public
$22.78
-1.75-7.13%
At close: Sep 17, 5:00 PM EST
$22.78
N/A
After Hours: 4:00 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Damora Therapeutics (DMRA) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$24.96
Close
$22.78
Volume / Avg.
605.11K / 604.50K
Day Range
$22.74 - $25.49
52 Wk Range
16.50 - 34.89
Market Cap
$1.41B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
31
Short Interest
7.81%
Days to Cover
13.27

Recent Damora Therapeutics Inc News

This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Top Wall Street analysts changed outlook on several top stocks. See all changes on analyst ratings page.
Avi Kapoor

This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Wall Street analysts change outlook on top stocks, including LIME, CIFR, BSP, DMRA, and ITG. Check analyst ratings page for full view.
Avi Kapoor

Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
Avi Kapoor

This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings.
Avi Kapoor

PRO
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from
Benzinga Newsdesk

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-44.52M
Investing Cash Flow (TTM)
-
Financing Cash Flow (TTM)
592.27M
Free Cash Flow (TTM)
-44.52M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
530.38M

Analyst Trends and Forecast

1
Mar
1
Apr
1
May
2
Jun
3
Jul
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
4.4
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$1.67B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
3.92
Earnings Yield % (TTM)
-1.06%
Earnings Yield % (FWD)
-7.96%
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$6.25

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$540.52M
Debt to Equity
-
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$24.96
Close
$22.78
Volume / Avg.
605.11K / 604.50K
Day Range
$22.74 - $25.49
52 Wk Range
16.50 - 34.89
Market Cap
$1.41B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
31
Short Interest
7.81%
Days to Cover
13.27

About

Sector
Health Care
Industry
Biotechnology
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, ...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Damora Therapeutics (DMRA) stock?

A

You can purchase shares of Damora Therapeutics (NASDAQ:DMRA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Damora Therapeutics (DMRA) competitors?

Q

What is the forecast, or price target, for Damora Therapeutics (DMRA) stock?

A

Damora Therapeutics has a consensus price target of $44.20.

Q

What is the current price for Damora Therapeutics (DMRA)?

A

The stock price for Damora Therapeutics (NASDAQ: DMRA) is $22.78 last updated September 17, 2026 at 4:00 PM EDT.

Q

Does Damora Therapeutics (DMRA) pay a dividend?

A

There are no upcoming dividends for Damora Therapeutics.

Q

When is Damora Therapeutics (NASDAQ:DMRA) reporting earnings?

A

Damora Therapeutics does not have any upcoming earnings scheduled.

Q

Is Damora Therapeutics (DMRA) going to split?

A

There is no upcoming split for Damora Therapeutics.

Q

What sector and industry does Damora Therapeutics (DMRA) operate in?

A

Damora Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved